Results 171 to 180 of about 514,735 (343)

SYNERGISM IN IMMUNOSUPPRESSION

open access: bronze, 1971
Eli A. Friedman   +2 more
openalex   +2 more sources

Antimyelin antibody in multiple sclerosis: no change during immunosuppression [PDF]

open access: bronze, 1977
L D Wilkerson   +3 more
openalex   +1 more source

ORL@Cu‐MOF Boost Cuproptosis and Suppress Fatty Acid Metabolism for Cancer Lymph Node Metastasis Synergistic Therapy

open access: yesAdvanced Science, EarlyView.
The fabrication of ORL@Cu‐MOF and the mechanism of synergistic therapy by cuproptosis, reprogram fatty acid metabolism and anti‐PD‐1. Abstract Lymph node metastasis (LNM) is one of the significant characteristics of poor prognosis in oral squamous cell carcinoma (OSCC), strongly associated with high mortality rates.
Zi‐Zhan Li   +11 more
wiley   +1 more source

Late BK Nephropathy 15 years post kidney transplant following chemotherapy: A case report. [PDF]

open access: yesIDCases
Hamiduzzaman A   +5 more
europepmc   +1 more source

Sunscreens and Immunosuppression

open access: yesJournal of Investigative Dermatology, 1996
Lee K. Roberts   +3 more
openaire   +2 more sources

Critical Role of IL1R2‐ENO1 Interaction in Inhibiting Glycolysis‐Mediated Pyroptosis for Protection Against Lethal Sepsis

open access: yesAdvanced Science, EarlyView.
The authors have discovered that intracellular interleukin 1 receptor 2 (IL1R2) negatively regulates pyroptosis and inflammation by inhibiting glycolysis in sepsis. Soluble IL1R2 is released from macrophages undergoing pyroptosis. IL1R2 acts as a novel negative regulator of glycolysis by interacting with enolase 1 (ENO1), thereby inhibiting gasdermin D
Chuyi Tan   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy